C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation: small molecules that tag disease-causing proteins for the cell’s natural recycling machinery. Its proprietary TORPEDO platform designs both heterobifunctional (BiDAC) and molecular-glue (MonoDAC) degraders, as well as payloads for degrader-antibody conjugates. Programs center on oncology and other hard-to-treat diseases, including collaborations that apply the platform to external targets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 7.2 | — | -26.3 | — |
| Q2 2025 | 6.5 | — | -26 | — |
| Q3 2025 | 11.2 | — | -32.2 | — |
| Q4 2025 | 11 | — | -20.5 | — |
| Q1 2026 | 6.2 | -15% | -25.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Gladstone Capital Corporation (GLAD), Concrete Pumping Holdings, Inc. (BBCP), Citizens & Northern Corporation (CZNC), Starz Entertainment Corp. (STRZ), Powerlaw Corp. (PWRL), Rezolute, Inc. (RZLT)